Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Pfizer Inc. unveiled a licensing deal on 30 June for Spero Therapeutics, Inc. SPR206, an intravenously-administered polymyxin candidate being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting